NCT04114188View on ClinicalTrials.gov

Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Renal Transplant Rejection
Interventions
DRUG

Antithymocyte Immunoglobulin (Rabbit)

1st kidney transplant recipients (low risk: PRA/cPRA \< 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.

Trial Locations (1)

13353

Charité University Medicine Berlin, Berlin

All Listed Sponsors
collaborator

Institut Klinické a Experimentální Medicíny

UNKNOWN

lead

Prof. Dr. Petra Reinke

OTHER

NCT04114188 - Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI) | Biotech Hunter | Biotech Hunter